...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Benefit of Primary Prophylaxis Before 18 Months of Age in Reducing the Incidence of Pneumocystis carinii Pneumonia and Early Death in a Cohort of 112 Human Immunodeficiency Virus-infected Infants
【24h】

Benefit of Primary Prophylaxis Before 18 Months of Age in Reducing the Incidence of Pneumocystis carinii Pneumonia and Early Death in a Cohort of 112 Human Immunodeficiency Virus-infected Infants

机译:在112个人类免疫缺陷病毒感染的婴儿队列中,进行18个月大的主要预防措施可减少卡氏肺孢子虫肺炎的发生和早期死亡的益处

获取原文
           

摘要

Objective . To determine the effectiveness of primary prophylaxis in preventing Pneumocystis carinii pneumoni (PCP) in children with perinatally acquired human immunodeficiency virus 1 (HIV-1) infection.Methods . We conducted a retrospective analysis of a cohort of infants followed from birth at six metropolitan hospitals and one outpatient clinic for pregnant, drugusing women in New York City. Outcomes measured were histologically confirmed PCP and/or death. The potential confounding effect of the infant's stage of illness, as determined by CD4 count, was controlled by including all CD4 determinations as time-dependant covariates in a Cox proportional hazards analysis. Cases were censored at PCP onset, death, loss to follow-up, and 18 months of age.Results . One hundred twelve HIV-infected children were enrolled at birth between 1986 and 1993. Sixty of these were tracked beyond 18 months of age; of the others, 21 died before this age, 4 were considered lost to follow-up, and 27 had not reached 18 months of age at the last visit. Only 3 cases (4%) of confirmed PCP occurred among the 70 children who received primary PCP proprophylaxis before 18 months of age, compared with 12 cases (28%) among 42 children not receiving PCP prophylaxis at any point before 18 months of age. The Kaplan-Meier estimated incidence of PCP in the first year among children not receiving prophylaxis was 25% (95% confidence interval [CI], 12 to 39). Using Cox methods, the unadjusted risk of PCP among infants not receiving prophylaxis, relative to those receiving it, was 4.1 (95% CI, 1.1 to 15); the relative risk was 4.4 (95% CI, 1.2 to 17) adjusting for the percentage of CD4-positive lymphocytes and 5.1 (95% CI, 1.3 to 20) adjusting for the absolute number of CD4-positive cells. Eight of 26 deaths were caused by PCP, and the likelihood of early death was significantly diminished if PCP prophylaxis was given (relative risk controlling for absolute CD4 cells, 2.57; 95% CI, 1.1 to 6.1).Conclusions . We report evidence that primary antimicrobial PCP prophylaxis is highly effective in decreasing the frequency of PCP and early death in infants with perinatal HIV infection. These findings support the evised National Pediatric HIV Resource Center and Centers for Disease Control and Prevention guidelines for PCP prophylaxis in children.
机译:目标。目的确定初级预防措施在围产期获得性人免疫缺陷病毒1(HIV-1)感染儿童中预防卡氏肺孢子虫(PCP)的有效性。我们对纽约市六家大都市医院和一家门诊,孕妇,吸毒妇女的出生后婴儿进行了回顾性分析。所测量的结果在组织学上已确认为PCP和/或死亡。通过CD4计数确定的婴儿患病阶段的潜在混杂效应,是通过将所有CD4测定作为时间依赖性协变量纳入Cox比例风险分析中来控制的。在PCP发病,死亡,失访和18个月大时对病例进行检查。 1986年至1993年之间,有112名受HIV感染的儿童入选。其中有60名被追踪到18个月以上。在其他人中,有21人在该年龄之前死亡,有4人被认为失去随访,而27人在上次探视时未达到18个月大。在18个月大以前接受过PCP预防的70名儿童中,只有3例(4%)确诊为PCP,而在18个月之前任何时候未接受PCP预防的42名儿童中有12例(28%)。 Kaplan-Meier估计未接受预防的儿童中第一年PCP的发生率为25%(95%置信区间[CI]为12至39)。使用Cox方法,未接受预防的婴儿相对于接受预防的婴儿未经调整的PCP风险为4.1(95%CI,1.1至15);相对于CD4阳性淋巴细胞的百分比,相对风险为4.4(95%CI,1.2至17),对于CD4阳性细胞的绝对数量,相对风险为5.1(95%CI,1.3至20)。 26例死亡中有8例是由PCP引起的,如果给予PCP预防,早期死亡的可能性将大大降低(控制绝对CD4细胞的相对风险为2.57; 95%CI为1.1至6.1)。我们报告的证据表明,初级预防性PCP预防在降低围产期HIV感染婴儿的PCP频率和早期死亡方面非常有效。这些发现支持了已建立的全国儿童艾滋病毒资源中心和疾病预防控制中心儿童预防五氯苯酚的指南。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号